Your browser is no longer supported. Please, upgrade your browser.
ZYNE Zynerba Pharmaceuticals, Inc. daily Stock Chart
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own10.80% Shs Outstand14.63M Perf Week-9.15%
Market Cap133.72M Forward P/E- EPS next Y-2.63 Insider Trans7.85% Shs Float10.75M Perf Month-16.38%
Income-32.00M PEG- EPS next Q-0.66 Inst Own31.80% Short Float20.05% Perf Quarter-23.71%
Sales- P/S- EPS this Y3.90% Inst Trans7.31% Short Ratio6.51 Perf Half Y45.08%
Book/sh4.54 P/B2.01 EPS next Y-7.60% ROA-41.90% Target Price17.69 Perf Year-52.27%
Cash/sh4.27 P/C2.14 EPS next 5Y- ROE-46.60% 52W Range5.42 - 25.95 Perf YTD-27.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.05% Beta-
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low72.14% ATR0.57
Employees22 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)41.11 Volatility4.95% 6.10%
OptionableYes Debt/Eq0.00 EPS Q/Q15.10% Profit Margin- Rel Volume0.51 Prev Close9.14
ShortableYes LT Debt/Eq0.00 EarningsMar 26 BMO Payout- Avg Volume331.09K Price9.33
Recom2.00 SMA20-4.65% SMA50-13.79% SMA200-20.13% Volume99,827 Change2.08%
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Dec-22-16Initiated Cantor Fitzgerald Overweight $28
Dec-06-16Resumed Jefferies Buy
Oct-07-16Initiated H.C. Wainwright Buy $22
Nov-12-15Reiterated Oppenheimer Outperform $40 → $34
Sep-08-15Initiated Oppenheimer Outperform $40
Mar-22-18 06:45AM  Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN) GlobeNewswire
Mar-15-18 07:26PM  Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Simply Wall St.
Mar-14-18 09:00AM  Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-13-18 08:20AM  Todays Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals ACCESSWIRE
Mar-12-18 06:53AM  Zynerba reports 4Q loss Associated Press +15.21%
06:45AM  Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights GlobeNewswire
Mar-07-18 07:10AM  Wired News Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy ACCESSWIRE
Mar-05-18 02:50PM  Main Line pharma company plans key study of Fragile X syndrome therapy American City Business Journals
06:45AM  Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing GlobeNewswire
Jan-31-18 01:39PM  Look Beyond Pharma to Invest in Marijuana Industry Insider Monkey
Jan-29-18 02:05PM  Can Zynerba Pharma Shares Really Still Double in These High Times? 24/7 Wall St. +6.05%
Jan-03-18 04:30PM  Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update GlobeNewswire
Dec-23-17 10:31AM  Can This Beaten-Down Marijuana Stock Roar Back in 2018? Motley Fool
Dec-17-17 07:30PM  Canadas Cannabis Market Could Be About To Explode
Dec-13-17 03:24PM  Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend? Simply Wall St.
Dec-05-17 08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals ACCESSWIRE
Dec-04-17 12:32PM  Zynerba Pharmaceuticals Volatile After Epilepsy Study Results Benzinga -8.30%
Dec-03-17 12:01PM  Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Nov-21-17 09:00AM  Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire +5.43%
Nov-20-17 05:15PM  Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)? Simply Wall St.
Nov-14-17 07:34AM  Zynerba reports 3Q loss Associated Press +11.07%
07:30AM  Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights GlobeNewswire
Nov-07-17 07:30AM  Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Oct-16-17 08:21AM  3 Marijuana Stocks That Like to Live Life Dangerously Motley Fool
Oct-04-17 08:39AM  Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week Motley Fool
Sep-29-17 04:52PM  Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain Benzinga -11.44%
10:32AM  Zynerba Stock: Where Is It Headed From Here? Investopedia
09:32AM  Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
09:15AM  Why Zynerba's stock soared 62% this week American City Business Journals
08:10AM  Today's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology ACCESSWIRE
Sep-28-17 04:32PM  Zynerba Pharma (ZYNE) Stock Soars on Positive Cannabis-Based Drug Results Zacks +52.50%
09:25AM  Zynerba Pharma Wins Big on Cannabis Trial 24/7 Wall St.
06:30AM  Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome GlobeNewswire
Sep-27-17 08:38AM  This Marijuana Stock May Already Be Running Out of Chances to Succeed Motley Fool +5.99%
Sep-18-17 07:30PM  5 Top Marijuana Stocks For 2017
Sep-15-17 08:33AM  Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year Motley Fool
Sep-06-17 07:30AM  Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-23-17 08:38AM  2 Marijuana Stocks That Have Imploded Since August Began Motley Fool
Aug-18-17 09:18AM  What's The Difference Between Zynerba and GW Pharma's Epilepsy Drugs? Benzinga
Aug-16-17 03:44PM  Zynerba's Pain Could Be GW Pharmaceuticals' Gain Motley Fool
08:38AM  Up in Smoke: This Marijuana Stock Lost More Than Half Its Value Last Week Motley Fool
Aug-14-17 11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks -8.68%
10:10AM  Zynerba Midstage Cannabinoid Trial Falls Short 24/7 Wall St.
09:38AM  Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward
08:00AM  Zynerba Pharmaceuticals Upcoming Catalysts and Price Targets ACCESSWIRE
06:45AM  Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis GlobeNewswire
Aug-11-17 07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-10-17 08:37AM  Are Options Traders Betting on a Big Move in Zynerba Pharmaceuticals (ZYNE) Stock? Zacks
08:00AM  Today's Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals ACCESSWIRE
Aug-08-17 08:36AM  The Market In 5 Minutes Benzinga -6.00%
07:15AM  Zynerba Pharmas failed cannabidiol gel trial has upside for rival GW Pharma MarketWatch
Aug-07-17 10:34AM  Zynerba shares plunge as cannabis-based epilepsy gel fails study Reuters -55.71%
08:06AM  3 Stocks to Watch on Monday: Alphabet Inc (GOOGL), Zynerba Pharmaceuticals Inc (ZYNE) and Sony Corp (ADR) (SNE) InvestorPlace
08:06AM  Zynerba Pharma shares plummet 53% on failed trial for cannabidiol gel in epilepsy MarketWatch
07:00AM  Zynerba's cannabis-based gel for epilepsy fails study Reuters
06:45AM  Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures GlobeNewswire
Aug-03-17 05:09PM  It's High Time For The Cannabis-Related Drug Pipeline Benzinga
Aug-02-17 08:06AM  These 2 Marijuana Stocks Moved in Completely Opposite Directions Last Week Motley Fool -7.30%
Aug-01-17 09:44PM  Zynerba reports 2Q loss Associated Press +6.81%
03:38PM  Cantor Weighs in on Zynerba Pharmaceuticals Inc (ZYNE) as Phase 2 Readouts Approaching SmarterAnalyst
11:59AM  Here's What You Need To Know About Zynerba Pharmaceuticals Benzinga
07:30AM  Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights GlobeNewswire
Jul-28-17 07:30AM  Zynerba Pharmaceuticals Mourns Passing of Director Cynthia A. Rask GlobeNewswire
Jul-19-17 08:39AM  These 4 Marijuana Stocks All Jumped at Least 10% Last Week Motley Fool
Jul-18-17 08:03AM  Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys Motley Fool
Jul-14-17 08:02AM  5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals Motley Fool
Jul-11-17 01:58PM  Top Biotech Manager Sells Arena Pharmaceuticals On Today's Big Gain Forbes
08:00AM  Today's Research Reports on Trending Tickers: Insys Therapeutics and Zynerba Pharmaceuticals Accesswire
Jul-08-17 08:27AM  Wow! 92% of Patients Prefer Medical Marijuana to Opioids, New Survey Shows Motley Fool
Jul-03-17 08:29AM  4 Marijuana Stocks Looking to Combat the Opioid Epidemic Motley Fool
Jun-26-17 07:45AM  Zynerba Pharmaceuticals Added to the Russell 3000® Index GlobeNewswire
07:30AM  Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program GlobeNewswire
Jun-23-17 04:40PM  Pot Stock Winners of the Week Investopedia
Jun-15-17 11:24AM  Cannabis Is Todd Hagopian's Top Biotech Sub-Sector Forbes
Jun-12-17 04:17PM  Maxim Bullish on Zynerba Pharmaceuticals Inc (ZYNE) Following Meeting with Management SmarterAnalyst -8.74%
Jun-11-17 11:03AM  Marijuana Stock Investors in Awe as California Goes Toe-to-Toe With the Trump Administration Motley Fool
Jun-08-17 07:30AM  Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome GlobeNewswire
Jun-02-17 01:24PM  Better Know a Marijuana Stock: Zynerba Pharmaceuticals Motley Fool
Jun-01-17 08:16AM  Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-10-17 02:46PM  Zynerba reports 1Q loss Associated Press
May-09-17 07:30AM  Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights GlobeNewswire -6.99%
May-08-17 05:29PM  ETFs with exposure to Zynerba Pharmaceuticals, Inc. : May 8, 2017 Capital Cube
Apr-27-17 04:22PM  ETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 27, 2017 Capital Cube
Apr-17-17 01:13PM  ETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 17, 2017 Capital Cube
08:20AM  Yikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016 Motley Fool
Apr-12-17 08:47AM  Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options Zacks
Apr-05-17 05:49PM  ETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 5, 2017 Capital Cube
Mar-31-17 01:04PM  ZYNERBA PHARMACEUTICALS, INC. Financials
Mar-29-17 10:53AM  Zynerba Pharmaceuticals, Inc. :ZYNE-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017 Capital Cube
Mar-28-17 09:04AM  Edited Transcript of ZYNE earnings conference call or presentation 27-Mar-17 12:30pm GMT Thomson Reuters StreetEvents -5.39%
Mar-27-17 08:30AM  Zynerba Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today +7.68%
08:11AM  ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:07AM  Q4 2016 Zynerba Pharmaceuticals Inc Earnings Release - Before Market Open
06:48AM  Zynerba reports 4Q loss Associated Press
06:30AM  Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights GlobeNewswire
Mar-22-17 04:07PM  Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed Insider Monkey
Mar-17-17 08:15AM  Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14% Zacks
Mar-13-17 07:35AM  Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017 GlobeNewswire
07:30AM  Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis GlobeNewswire
07:21AM  ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Ex
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAPP MICHAEL10% OwnerJan 02Buy12.9915,000194,8471,469,115Jan 03 06:05 AM
RAPP MICHAEL10% OwnerOct 23Buy9.9425,745255,7951,454,115Oct 23 07:25 PM
RAPP MICHAEL10% OwnerOct 20Buy9.7830,000293,5381,428,370Oct 23 07:25 PM
RAPP MICHAEL10% OwnerOct 19Buy9.5944,255424,4051,398,370Oct 23 07:25 PM
ANIDO ARMANDOChairman & Chief Exec. OfficerMay 15Buy19.571,50029,355337,512May 16 08:50 AM
Fickenscher James EChief Financial OfficerMay 12Buy19.825,200103,06412,200May 16 08:50 AM
ANIDO ARMANDOChairman & Chief Exec. OfficerMay 12Buy19.763,50069,160336,012May 16 08:50 AM